FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3159010801> ?p ?o ?g. }

• W3159010801 endingPage "498" @default.
• W3159010801 startingPage "491" @default.
• W3159010801 abstract "Atezolizumab, a programmed-death ligand-1 (PD-L1) inhibitor, is a novel treatment option for patients with metastatic urothelial cancer (mUC). Clinical prognostic factors, survival outcomes, and the safety of patients with mUC treated with atezolizumab, in a real-world setting, were investigated.62 patients with mUC, treated at the Institute of Oncology Ljubljana between May 8th 2018 and Dec 31st 2019, were included. Response rates and immune-related adverse events (irAE) were collected. Progression-free survival and overall survival times were assessed using the Kaplan-Meier method. The Cox proportional hazards model was applied to identify the factors affecting survival.Of 62 patients, five (8.1%) have not yet been evaluated and 20 (32%) died prior to the first radiographic evaluation. We observed clinical benefit in 19 (33%), objective response in 12 (21%), and complete response in five (9%) patients. Median overall survival for the whole population was 6.8 (95% CI, 2.6-11.0), for platinum-naïve 8.7 (95% CI: 0.8-16.5), and for the platinum-treated group 6.8 (95% CI, 3.7-10) months. At the 5.8 (0.3-23.1) month median follow-up, the median duration of the response was not reached. IrAE occurred in 20 (32%) patients and seven (11%) of them discontinued the treatment. Multivariate analysis in platinum-treated patients showed that a treatment-free interval of more than six months was prognostic for overall survival (OS).Responses to atezolizumab led to long disease remission in a subset of our patients. The median OS in our real-world population was compromised by a large percentage of patients with poor ECOG performance status (PS). A treatment-free interval from chemotherapy was associated with the longer survival of platinum-treated patients with mUC receiving further atezolizumab." @default.
• W3159010801 created "2021-05-10" @default.
• W3159010801 creator A5014888987 @default.
• W3159010801 creator A5036382199 @default.
• W3159010801 creator A5061562652 @default.
• W3159010801 date "2021-05-04" @default.
• W3159010801 modified "2023-10-06" @default.
• W3159010801 title "Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice" @default.
• W3159010801 cites W1752338025 @default.
• W3159010801 cites W2033775272 @default.
• W3159010801 cites W2058786880 @default.
• W3159010801 cites W2102116016 @default.
• W3159010801 cites W2119642155 @default.
• W3159010801 cites W2132379894 @default.
• W3159010801 cites W2152762320 @default.
• W3159010801 cites W2221837786 @default.
• W3159010801 cites W2289712604 @default.
• W3159010801 cites W2414977199 @default.
• W3159010801 cites W2470163336 @default.
• W3159010801 cites W2559804019 @default.
• W3159010801 cites W2578096561 @default.
• W3159010801 cites W2582671354 @default.
• W3159010801 cites W2604441970 @default.
• W3159010801 cites W2604535399 @default.
• W3159010801 cites W2607272476 @default.
• W3159010801 cites W2760661635 @default.
• W3159010801 cites W2777192533 @default.
• W3159010801 cites W2794050015 @default.
• W3159010801 cites W2810397648 @default.
• W3159010801 cites W2930221971 @default.
• W3159010801 cites W2933397876 @default.
• W3159010801 cites W2938353934 @default.
• W3159010801 cites W2940343603 @default.
• W3159010801 cites W2944314174 @default.
• W3159010801 cites W2947818354 @default.
• W3159010801 cites W2949867377 @default.
• W3159010801 cites W2996343037 @default.
• W3159010801 cites W3024551702 @default.
• W3159010801 cites W3087464965 @default.
• W3159010801 cites W3096916085 @default.
• W3159010801 cites W4313635027 @default.
• W3159010801 doi "https://doi.org/10.2478/raon-2021-0021" @default.
• W3159010801 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33939898" @default.
• W3159010801 hasPublicationYear "2021" @default.
• W3159010801 type Work @default.
• W3159010801 sameAs 3159010801 @default.
• W3159010801 citedByCount "3" @default.
• W3159010801 countsByYear W31590108012022 @default.
• W3159010801 countsByYear W31590108012023 @default.
• W3159010801 crossrefType "journal-article" @default.
• W3159010801 hasAuthorship W3159010801A5014888987 @default.
• W3159010801 hasAuthorship W3159010801A5036382199 @default.
• W3159010801 hasAuthorship W3159010801A5061562652 @default.
• W3159010801 hasBestOaLocation W31590108011 @default.
• W3159010801 hasConcept C121608353 @default.
• W3159010801 hasConcept C126322002 @default.
• W3159010801 hasConcept C143998085 @default.
• W3159010801 hasConcept C197934379 @default.
• W3159010801 hasConcept C207103383 @default.
• W3159010801 hasConcept C2775949291 @default.
• W3159010801 hasConcept C2776694085 @default.
• W3159010801 hasConcept C2777701055 @default.
• W3159010801 hasConcept C2779134260 @default.
• W3159010801 hasConcept C2780057760 @default.
• W3159010801 hasConcept C2908647359 @default.
• W3159010801 hasConcept C38180746 @default.
• W3159010801 hasConcept C44249647 @default.
• W3159010801 hasConcept C50382708 @default.
• W3159010801 hasConcept C71924100 @default.
• W3159010801 hasConcept C99454951 @default.
• W3159010801 hasConceptScore W3159010801C121608353 @default.
• W3159010801 hasConceptScore W3159010801C126322002 @default.
• W3159010801 hasConceptScore W3159010801C143998085 @default.
• W3159010801 hasConceptScore W3159010801C197934379 @default.
• W3159010801 hasConceptScore W3159010801C207103383 @default.
• W3159010801 hasConceptScore W3159010801C2775949291 @default.
• W3159010801 hasConceptScore W3159010801C2776694085 @default.
• W3159010801 hasConceptScore W3159010801C2777701055 @default.
• W3159010801 hasConceptScore W3159010801C2779134260 @default.
• W3159010801 hasConceptScore W3159010801C2780057760 @default.
• W3159010801 hasConceptScore W3159010801C2908647359 @default.
• W3159010801 hasConceptScore W3159010801C38180746 @default.
• W3159010801 hasConceptScore W3159010801C44249647 @default.
• W3159010801 hasConceptScore W3159010801C50382708 @default.
• W3159010801 hasConceptScore W3159010801C71924100 @default.
• W3159010801 hasConceptScore W3159010801C99454951 @default.
• W3159010801 hasIssue "4" @default.
• W3159010801 hasLocation W31590108011 @default.
• W3159010801 hasLocation W31590108012 @default.
• W3159010801 hasLocation W31590108013 @default.
• W3159010801 hasLocation W31590108014 @default.
• W3159010801 hasOpenAccess W3159010801 @default.
• W3159010801 hasPrimaryLocation W31590108011 @default.
• W3159010801 hasRelatedWork W2361700749 @default.
• W3159010801 hasRelatedWork W2381345080 @default.
• W3159010801 hasRelatedWork W2572837865 @default.
• W3159010801 hasRelatedWork W2896583732 @default.
• W3159010801 hasRelatedWork W2948845624 @default.

• next